APLS
ApellisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
APLS Profile
Apellis Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company focused on the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade
100 Fifth Avenue
, Waltham
, MA 02451
--
Apellis Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on September 25, 2009. The Company is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds for the treatment of diseases with high unmet need by inhibiting the complement system (as a component of the immune system) at the level of central protein C3 in the complement cascade. In February 2023, the U.S. Food and Drug Administration (FDA) approved SYFOVRE, the first drug approved for the treatment of geographic atrophy secondary to age-related macular degeneration (GA).
